MGLL and fatty liver disease: Despite increased 2-AG concentrations, MGL−/− mice do not develop hepatic steatosis [24] and are protected from hepatic injury by a mechanism that involves increased endocannabinoid signaling via CB2R and reduced production of eicosanoids in the liver [35].